NASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis $63.25 +1.22 (+1.97%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$61.72▼$63.3950-Day Range$58.53▼$68.8252-Week Range$48.20▼$70.81Volume179,333 shsAverage Volume148,026 shsMarket Capitalization$1.33 billionP/E Ratio39.53Dividend YieldN/APrice Target$82.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get ANI Pharmaceuticals alerts: Email Address ANI Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside30.8% Upside$82.75 Price TargetShort InterestHealthy1.86% of Shares Sold ShortDividend StrengthN/ASustainability-2.48Upright™ Environmental ScoreNews Sentiment0.56Based on 2 Articles This WeekInsider TradingSelling Shares$10.72 M Sold Last QuarterProj. Earnings Growth25.90%From $3.32 to $4.18 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.84 out of 5 starsMedical Sector32nd out of 936 stocksPharmaceutical Preparations Industry8th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageANI Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about ANI Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.86% of the outstanding shares of ANI Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ANI Pharmaceuticals has recently increased by 5.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreANI Pharmaceuticals has received a 36.91% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Beta blockers (C07)", "Macrolides", "Antifungal medication (D01) ", "Cyclophosphamide", and "Calcium channel blockers (C08)" products. See details.Environmental SustainabilityThe Environmental Impact score for ANI Pharmaceuticals is -2.48. Previous Next 2.5 News and Social Media Coverage News SentimentANI Pharmaceuticals has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ANI Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest6 people have searched for ANIP on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows5 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,719,774.00 in company stock.Percentage Held by Insiders12.70% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ANI Pharmaceuticals' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 25.90% in the coming year, from $3.32 to $4.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is 39.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.45.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is 39.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 164.48.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ANI Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About ANI Pharmaceuticals Stock (NASDAQ:ANIP)ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Read More ANIP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIP Stock News HeadlinesJuly 18, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Sells $697,180.00 in StockJuly 16, 2024 | insidertrades.comInsider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 250 Shares of StockJuly 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 3, 2024 | insidertrades.comChad Gassert Sells 20,000 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockJuly 19, 2024 | americanbankingnews.comMuthusamy Shanmugam Sells 14,257 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockJuly 19, 2024 | americanbankingnews.comMuthusamy Shanmugam Sells 11,000 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockJuly 18, 2024 | americanbankingnews.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of "Buy" from AnalystsJuly 16, 2024 | americanbankingnews.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook Sells 250 Shares of StockJuly 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 15, 2024 | globenewswire.comANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral PowderJuly 2, 2024 | globenewswire.comANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USPJune 25, 2024 | globenewswire.comANI Pharmaceuticals' CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award WinnerJune 24, 2024 | globenewswire.comANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera SciencesJune 10, 2024 | seekingalpha.comANI Pharmaceuticals Is Undervalued, As Royalty Potential Is OverlookedMay 29, 2024 | globenewswire.comANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare ConferenceMay 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)May 20, 2024 | markets.businessinsider.comANI Pharma Launches Kionex Suspension For Oral Or Rectal UseMay 20, 2024 | globenewswire.comANI Pharmaceuticals Announces the Launch of Kionex® SuspensionSee More Headlines Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CUSIPN/A CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees600Year FoundedN/APrice Target and Rating Average Stock Price Target$82.75 High Stock Price Target$94.00 Low Stock Price Target$77.00 Potential Upside/Downside+30.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$1.60 Trailing P/E Ratio39.53 Forward P/E Ratio19.05 P/E GrowthN/ANet Income$18.78 million Net Margins6.87% Pretax Margin8.32% Return on Equity17.15% Return on Assets8.29% Debt Debt-to-Equity Ratio0.63 Current Ratio3.95 Quick Ratio3.12 Sales & Book Value Annual Sales$486.82 million Price / Sales2.72 Cash Flow$6.41 per share Price / Cash Flow9.86 Book Value$21.13 per share Price / Book2.99Miscellaneous Outstanding Shares20,970,000Free Float18,309,000Market Cap$1.33 billion OptionableOptionable Beta0.75 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Nikhil Lalwani (Age 46)President, CEO & Director Comp: $2.32MMr. Stephen P. Carey (Age 53)Senior VP of Finance & CFO Comp: $1.11MMr. Chad Gassert (Age 48)Senior Vice President of Corporate Development & Strategy Comp: $849.71kMr. Christopher K. Mutz (Age 52)Senior Vp & Head of Rare Disease Comp: $867.92kMr. Ori Gutwerg (Age 49)Senior Vice President of Generics Comp: $895.16kMr. Muthusamy Shanmugam MS R.Ph. (Age 56)Head of R&D, COO of Novitium Operations & Director Mr. James G. Marken (Age 61)Senior Vice President of Operations & Product Development Comp: $673.23kMs. Meredith W. Cook (Age 49)Senior VP, General Counsel & Corporate Secretary Ms. Krista L. Davis (Age 50)Senior VP & Chief Human Resources Officer Ms. Elizabeth Powell J.D.Chief Compliance Officer & Head of Legal of Rare DiseaseMore ExecutivesKey CompetitorsConcert PharmaceuticalsNASDAQ:CNCEProgenics PharmaceuticalsNASDAQ:PGNXSelecta BiosciencesNASDAQ:SELBCytomX TherapeuticsNASDAQ:CTMXDURECTNASDAQ:DRRXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 12,865 shares on 7/26/2024Ownership: 0.625%Allspring Global Investments Holdings LLCBought 1,474 shares on 7/26/2024Ownership: 0.108%Legato Capital Management LLCBought 2,870 shares on 7/26/2024Ownership: 0.035%Louisiana State Employees Retirement SystemBought 200 shares on 7/24/2024Ownership: 0.037%Summit Global InvestmentsSold 7,390 shares on 7/22/2024Ownership: 0.037%View All Insider TransactionsView All Institutional Transactions ANIP Stock Analysis - Frequently Asked Questions How have ANIP shares performed this year? ANI Pharmaceuticals' stock was trading at $55.14 at the beginning of 2024. Since then, ANIP stock has increased by 14.7% and is now trading at $63.25. View the best growth stocks for 2024 here. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its quarterly earnings data on Friday, May, 10th. The specialty pharmaceutical company reported $0.95 EPS for the quarter, beating analysts' consensus estimates of $0.79 by $0.16. The specialty pharmaceutical company earned $137.43 million during the quarter, compared to analyst estimates of $125.01 million. ANI Pharmaceuticals had a net margin of 6.87% and a trailing twelve-month return on equity of 17.15%. What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO? 5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend. Who are ANI Pharmaceuticals' major shareholders? Top institutional investors of ANI Pharmaceuticals include Bank of New York Mellon Corp (0.63%), Assenagon Asset Management S.A. (0.36%), Wedge Capital Management L L P NC (0.30%) and Allspring Global Investments Holdings LLC (0.11%). Insiders that own company stock include Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Chad Gassert, Stephen P Carey, James G Marken, Christopher Mutz, Ori Gutwerg, Meredith Cook, Antonio R Pera, Krista Davis, Jeanne Thoma, Thomas Haughey and Patrick D Walsh. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA) and Broadcom (AVGO). This page (NASDAQ:ANIP) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free anip Stock Alerts